ACTG 265--SAFETY AND IMMUNOGENICITY OF LIVE ATTENUATED VARICELLA VACCINE

这项研究是一项I/II期的儿科ACTG试验，旨在研究免疫缺陷程度最低的HIV感染儿童使用减毒水痘活疫苗的安全性和免疫原性。目的是检查水痘减毒活疫苗对感染艾滋病毒的儿童的效果。需要回答的主要问题涉及疫苗在这些患者群体中使用时的安全性，以及这些受试者能够在多大程度上对疫苗产生免疫反应。将收集一组有野生型水痘病史的艾滋病毒感染者的数据。这些数据将被用来检查疫苗是否能够激发与针对疾病本身的免疫反应类似的免疫反应。

This study is a phase I/II pediatric ACTG trial of the safety and immunogenicity of live attenuated varicella vaccine in HIV-infected children with minimal immunodeficiency. The purpose is to examine the effects of a live-attenuated varicella vaccine on HIV-infected children. The primary questions to be answered concern the safety of the vaccine, when used within this patient population, and the extent to which these subjects are capable of mounting an immune response to the vaccine. Data from a comparison group of HIV-infected subjects with a history of wild type varicella, will be collected. The data will be used to examine whether the vaccine is capable of evoking immune responses similar to those mounted against the disease itself.